Valneva SE (NASDAQ:VALN) Short Interest Update

Valneva SE (NASDAQ:VALN) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 24,300 shares, a drop of 20.6% from the November 30th total of 30,600 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 30,000 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their price target on shares of Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, October 11th.

Valneva Stock Performance

Shares of VALN traded up $0.13 on Friday, reaching $4.33. 108,759 shares of the company’s stock traded hands, compared to its average volume of 16,618. The stock’s 50 day simple moving average is $4.70 and its two-hundred day simple moving average is $6.16. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The stock has a market cap of $351.86 million, a PE ratio of -33.31 and a beta of 1.98. Valneva has a 52-week low of $3.62 and a 52-week high of $10.76.

Institutional Investors Weigh In On Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC raised its position in Valneva SE (NASDAQ:VALN) by 33.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.